News
Find the latest news about Inaphaea BioLabs here
-
Inaphaea BioLabs welcomes Dr Gareth Griffiths
We are delighted to welcome Dr Gareth Griffiths to Inaphaea BioLabs as Scientific Consultant in our Scientific Advisory Support team. Gareth holds a PhD in Immunology and Oncology from the University of Birmingham and specialises in the isolation and growth of patient-derived tumour cells. After completing his PhD, he gained several years of postdoctoral experience…
-
Inaphaea BioLabs: the journey to setting up a new laboratory
Earlier this year, our parent company ValiRx announced the launch of Inaphaea BioLabs – a subsidiary company offering a wide range of pre-clinical and drug discovery testing services to academic, biotech, and pharmaceutical researchers. Inaphaea’s Preclinical Project Manager Zai Ahmad took on the task of setting up the new laboratory, drawing on her previous career…
-
Inaphaea BioLabs news roundup: July 2023
This roundup covers our news, updates, and highlights from July. It has been a particularly busy time for Inaphaea, and we’re looking forward to the lab’s official launch event with BioNow on 26 September, where we hope to see faces old and new. To discuss any of our updates, please contact Dr Andrew Carnegie, Head of…
-
Inaphaea BioLabs secures first external contract
Inaphaea has signed a Master Services Agreement and Project Statement of Work with a UK based biotech company. The first invoice has been issued relating to the work, with subsequent invoices anticipated at milestones during the project period. This defined work programme involves a multi-stage project and is expected to complete at the end of…
-
Inaphaea BioLabs news roundup: June 2023
In our new monthly news roundups, we will be sharing our news, updates, and highlights from the past few weeks.
-
Meet the Inaphaea BioLabs team: Melissa Barr, Lead Scientist
In the second instalment of our ‘meet the team’ series for Inaphaea BioLabs, we discover a little more about Melissa Barr.
-
Inaphaea BioLabs enters into agreement with OncoBone
Inaphaea BioLabs has entered into an agreement with virtual CRO services company, OncoBone Limited.
-
Imagen Therapeutics’ scientific assets to be transferred to Inaphaea BioLabs
ValiRx PLC, parent company of Inaphaea BioLabs, has announced the acquisition of the scientific assets of Imagen Therapeutics Limited.
-
Our services: immunoassays
Inaphaea are experts in developing immunoassays based on hormones and cytokines at our labs in MediCity, Nottingham as we strive to find new therapies in women’s health. In addition to our pre-validated models, our custom immunoassay services include the development, qualification, and validation of custom assays to meet your requirements. The types of assays we…
-
Our services: cell cancer assays
At our Inaphaea labs in MediCity, Nottingham we provide a comprehensive range of validated assays such as cell cancer assays or can provide assay development and validation for your bespoke assay as part of your project proposal. Cell-based assays play a crucial role in drug development and so at Inaphaea, we design the most relevant…